Aprea Therapeutics Q4 net loss narrows as R&D costs fall

Aprea Therapeutics

16/03/2026 12:09

Overview

Oncology drug developer's Q4 net loss narrowed from prior year

Q4 R&D expenses fell due to lower clinical trial costs and fewer personnel expenses

Outlook

Company expects cash and equivalents to fund operations into Q1 2027

Result Drivers

LOWER R&D EXPENSES - Decrease in R&D costs attributed to reduced expenses for ACESOT-1051 and paused ABOYA-119 trials, as well as lower personnel costs

Company press release: ID:nGNXbzpYMG

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
-$0.32
Q4 Net Income
-$2.50 mln
Q4 Operating Income
-$2.60 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Aprea Therapeutics Inc is $5.00, about 579.3% above its March 13 closing price of $0.74

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)